Investment analysts at ROTH Capital raised their price target on Spark Therapeutics, Inc. (ONCE) stock from $71.00 to $90.00 while maintaining a Buy rating.
The company reported positive top-line results from the Phase 3 pivotal trial of its lead gene therapy product candidate, SPK-RPE65, for the treatment of RPE65-mediated inherited retinal dystrophies. According to the principal investigator in the trial, they saw substantial restoration of vision in patients who were progressing toward complete blindness
Spark Therapeutics is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments.
Research analysts at Axiom Capital raised their price target on shares of Yahoo! Inc. (YHOO) from $39.00 to $41.00 while maintaining a Buy rating
Yahoo! is a guide focused on informing, connecting, and entertaining its users.
Nucor Corporation (NUE) was upgraded by stock analysts at Deutsche Bank from a Hold to a Buy rating with a price target of $52.00 per share
Nucor recently said that it expects third quarter 2015 earnings to be in the range of $0.45 to $0.50 per diluted share.
Nucor and its affiliates are manufacturers of steel products, with operating facilities primarily in the U.S. and Canada.
Brokerage firm Oppenheimer upgraded AutoZone, Inc. (AZO) stock from a Perform to an Outperform rating with a price target of $850.00 per share
AutoZone is the leading retailer and a leading distributor of automotive replacement parts and accessories in the United States.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance http://finance.crwe-pr.com/disclaimer/